Unlocking the New Era of Immunotherapies for Cancer and Autoimmune Disorders
The Immunotherapy stream at PEGS Boston unites the breakthrough science transforming how we engage, engineer, and reprogram the immune system to treat cancer, autoimmune disease, and beyond. Across three interconnected tracks, the program showcases breakthroughs in T-cell and immune-cell engagers, immune engineering, targeting, cellular therapies, and in vivo reprogramming powered by RNA and viral vectors. The Emerging T Cell Engagers track highlights innovative engager formats designed to improve safety, efficacy, and selectivity across solid tumors, autoimmune disease, and infectious disease. The Advances in Immunotherapy track examines new strategies to overcome resistance, address the tumor microenvironment, identify dark antigens, and advance cellular therapies for solid tumors and immune mediated conditions. The Next-Generation Immunotherapies track looks to the rapid development of
in vivo CAR Ts, targeted viral and nanoparticle platforms, payload and genome engineering, and the reprogramming of immune cells within the body. Join leading scientists advancing the next generation of immunotherapies from discovery through clinical translation.
Conferences Include:
May 10-11
Emerging T Cell Engagers
May 11-12
Advances in Immunotherapy
May 13-14
Next-Generation Immunotherapies